Clinical trials: Tumor Markers, Biological
Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).
- Trial name
- NCT02783599
- Testing
- Olaratumab, Doxorubicin, External Beam Radiotherapy
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 51 people
- Sponsor
- Eli Lilly and Company
Lungcancer
SHOX2_PTGER4 DNA Methlyation in Lung Cancer
Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis. In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a…
- Trial name
- Epi1 (NCT04321499)
- Testing
- lung cancer
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital, Essen
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART C (NCT05745714)
- Testing
- Ruxolitinib, Venetoclax, Dexamethasone
- Where
- 33 sites in Austria, Belgium and 12 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Glioblastoma, Malignant Glioma
Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics
The purpose of this study is to determine whether Q cells separated from the glioma sample are determinants in treatment response and prognosis of glioma patients
- Trial name
- NCT02047058
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanfang Hospital, Southern Medical University
PRE-HYPERTENSION
Cardiovascular Effects of Purple-Fleshed Potatoes
This study is being done to evaluate the effect on cardiovascular biomarkers and anthocyanin-derived plasma metabolites of Peruvian native purple-fleshed potato consumed over a 4-week period by prehypertensive men ages 18-40…
- Trial name
- NCT07734948
- Testing
- Purple flesh potato, White flesh potato
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Instituto de Investigacion Nutricional, Peru
Metastatic Melanoma, Recurrent Melanoma
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well aldesleukin with or without ziv-aflibercept works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7
- Trial name
- NCT01258855
- Testing
- Aldesleukin, Laboratory Biomarker Analysis, Ziv-Aflibercept
- Where
- 21 sites in United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Peritoneal Metastases
ctDNA as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer
This is a prospective, open-label, randomized controlled clinical trial, by monitoring the serum ctDNA mutational profile using NGS, aiming to elucidate the correlation between the postoperative ctDNA status and the assisted…
- Trial name
- NCT04752930
- Testing
- ctDNA monitoring, Imageology
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Prostate Cancer (Diagnosis)
miRNA Panel for PCa Diagnosis
This is a single-center, prospective diagnostic accuracy trial conducted at Renji Hospital, Shanghai Jiao Tong University School of Medicine, led by a team of urology and molecular medicine researchers.
- Trial name
- NCT07755592
- Testing
- Serum microRNA panel detection for prostate lesion differentiation
- Where
- China
- Volunteers
- 500 people
- Sponsor
- RenJi Hospital
Colorectal Neoplasm, Hereditary Nonpolyposis
Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers
This is a randomized, placebo-controlled Phase I/II multi-center trial, of the safety and efficacy of Celecoxib in a cohort of 81 HNPCC subjects and gene carriers.
- Trial name
- NCT00001693
- Testing
- Celecoxib (SC-58635)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Osteoporosis
Radiological Biological Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density
Rational: Osteoporosis in men is responsible for one third of fragility fractures. However the definition and especially the determinants of fracture in humans are less well known than in women.
- Trial name
- OSTEHOM (NCT01250314)
- Testing
- Radiology, Biological, biochemical and genetic samples
- Where
- France
- Volunteers
- 79 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Triple Negative Breast Cancer
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
TNBC is known for poor prognosis, aggressive patterns of disease, and significant molecular heterogeneity. (Neo)adjuvant chemotherapy (NACT) is standard of care in all node-positive and in node-negative patients with a tumour…
- Trial name
- ADAPT-TN-III (NCT06081244)
- Testing
- Sacituzumab govitecan, Pembrolizumab
- Where
- 43 sites in Germany
- Volunteers
- 348 people
- Sponsor
- Women's Cancer Study Group GmbH
Lung Cancer (Diagnosis)
Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection
The study is a prospective, non-randomized feasibility study evaluating blood sample and machine learning-based risk stratification for lung cancer in patients with COPD (chronic obstructive pulmonary disease).
- Trial name
- BREATHE (NCT07552584)
- Testing
- Risk stratification
- Where
- 2 sites in Denmark
- Volunteers
- 1,000 people
- Sponsor
- Vejle Hospital
Ovarian Cancer, Endometrial Cancer
Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors
This trial is a non-randomized, open label and multicenter study. It aims to : for endometrial cancer.:validate the 5-miR index assessed in plasma samples as a diagnostic marker to assess the risk of lymph node metastases for…
- Trial name
- GYNO-MIR (NCT03776630)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 363 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Cancer
Telomere Associated Variables (TAVs) in Prostate Cancer
This research project results from the interest in continuing the collaboration with the previous LL-HURS-ONC001 clinical validation study, which gives cause to the present study.
- Trial name
- NCT04124900
- Where
- 10 sites in United States, Spain
- Volunteers
- 509 people
- Sponsor
- Life Length SL
Neuroendocrine Carcinoma
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas
This is a randomized phase II non comparative study. Patients with metastatic Neuroendocrine Carcinomas (NEC) Grade 3, will be enrolled in the study and will be randomly assigned to receive FOLFIRI or CAPTEM as second line…
- Trial name
- SENECA (NCT03387592)
- Testing
- CPT-11, Calcio levofolinate, 5-Fluorouracil
- Where
- 23 sites in Italy
- Volunteers
- 53 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
COVID-19 Infection, Genitourinary Cancer
Impact of COVID-19 on GU Disease
The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: Complete an Online COVID-19 Questionnaire.
- Conditions
- COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions
- Trial name
- NCT04761107
- Where
- United States
- Volunteers
- 15,240 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer
Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy
RATIONALE: Tomato-soy juice may slow the growth of tumor cells. Studying samples of blood and tissue from patients with prostate cancer in the laboratory may help doctors identify biomarkers related to cancer.
- Trial name
- NCT01009736
- Testing
- tomato-soy juice, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cancer, Exercise Test
Pilot Study of the Haymakers for Hope Fitness Program
This research study is assessing the effect of an exercise program on cancer survivors. The exercise program is Haymakers for Hope 16-week exercise program
- Conditions
- Cancer, Exercise Test, Fatigue, Mood
- Trial name
- NCT04220216
- Testing
- H4H fitness program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Oesophageal Cancer, Gastric Cancer
Upper GI Serial Tumour Biopsies
This is a prospective translational research study in which tumour samples, blood samples and other biospecimens will be requested from patients with locally advanced or metastatic malignant oesophageal and gastric carcinoma.
- Trial name
- NCT05233007
- Testing
- Minor endoscopic biopsy
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- The Christie NHS Foundation Trust
Plasma Cell Myeloma
Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma
This study evaluates the association between a comprehensive geriatric assessment and laboratory biomarkers with the side effects of chemotherapy in older patients with multiple myeloma (MM).
- Trial name
- NCT05918185
- Testing
- Biospecimen Collection, Comprehensive Geriatric Assessment, Electronic Health Record Review
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.